Search Results - "Middelburg, Jim"

T-cell stimulating vaccines empower CD3 bispecific antibody therapy in solid tumors by Middelburg, Jim, Sluijter, Marjolein, Schaap, Gaby, Göynük, Büşra, Lloyd, Katy, Ovcinnikovs, Vitalijs, Zom, Gijs G., Marijnissen, Renoud J., Groeneveldt, Christianne, Griffioen, Lisa, Sandker, Gerwin G. W., Heskamp, Sandra, van der Burg, Sjoerd H., Arakelian, Tsolere, Ossendorp, Ferry, Arens, Ramon, Schuurman, Janine, Kemper, Kristel, van Hall, Thorbald

“…CD3 bispecific antibody (CD3 bsAb) therapy is clinically approved for refractory hematological malignancies, but responses in solid tumors have been limited so…”
Get full text

Longitudinal evaluation of the biodistribution and cellular internalization of the bispecific CD3xTRP1 antibody in syngeneic mouse tumor models by Sandker, Gerwin Gerhard Wemke, Middelburg, Jim, Wilbrink, Evienne, Molkenboer-Kuenen, Janneke, Aarntzen, Erik, van Hall, Thorbald, Heskamp, Sandra

“…BackgroundCD3 bispecific antibodies (CD3-bsAbs) require binding of both a tumor-associated surface antigen and CD3 for their immunotherapeutic effect. Their…”
Get full text

Preconditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy by Groeneveldt, Christianne, Kinderman, Priscilla, van den Wollenberg, Diana J M, van den Oever, Ruben L, Middelburg, Jim, Mustafa, Dana A M, Hoeben, Rob C, van der Burg, Sjoerd H, van Hall, Thorbald, van Montfoort, Nadine

“…BackgroundT-cell-engaging CD3-bispecific antibodies (CD3-bsAbs) are promising modalities for cancer immunotherapy. Although this therapy has reached clinical…”
Get full text

The MHC-E peptide ligands for checkpoint CD94/NKG2A are governed by inflammatory signals, whereas LILRB1/2 receptors are peptide indifferent by Middelburg, Jim, Ghaffari, Soroush, Schoufour, Tom A.W., Sluijter, Marjolein, Schaap, Gaby, Göynük, Büsra, Sala, Benedetta M., Al-Tamimi, Lejla, Scheeren, Ferenc, Franken, Kees L.M.C., Akkermans, Jimmy J.L.L., Cabukusta, Birol, Joosten, Simone A., Derksen, Ian, Neefjes, Jacques, van der Burg, Sjoerd H., Achour, Adnane, Wijdeven, Ruud H.M., Weidanz, Jon, van Hall, Thorbald

“…The immune checkpoint NKG2A/CD94 is a promising target for cancer immunotherapy, and its ligand major histocompatibility complex E (MHC-E) is frequently…”
Get full text

590 Pre-conditioning of the tumor microenvironment with oncolytic reovirus converts CD3-bispecific antibody treatment into effective immunotherapy by Groeneveldt, Christianne, Kinderman, Priscilla, Wollenberg, Diana JM van den, Oever, Ruben L van den, Middelburg, Jim, Mustafa, Dana AM, Hoeben, Rob, Burg, Sjoerd van der, Hall, Thorbald van, Montfoort, Nadine Van

“…BackgroundThe use of T cell-engaging CD3-bispecific antibodies (CD3-bsAbs) is a promising immunotherapeutic strategy for cancer. Although this therapy has…”
Get full text

Overcoming Challenges for CD3-Bispecific Antibody Therapy in Solid Tumors by Middelburg, Jim, Kemper, Kristel, Engelberts, Patrick, Labrijn, Aran F, Schuurman, Janine, van Hall, Thorbald

“…Immunotherapy of cancer with CD3-bispecific antibodies is an approved therapeutic option for some hematological malignancies and is under clinical…”
Get full text

A Single-Domain TCR-like Antibody Selective for the Qa-1b/Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint by Ghaffari, Soroush, Upchurch-Ange, Katherine, Gimlin, Susanne, Tripathi, Trivendra, Sluijter, Marjolein, Middelburg, Jim, van Hall, Thorbald, Weidanz, Jon

“…Abstract The NKG2A/HLA-E axis is an immune checkpoint that suppresses immune effector activity in the tumor microenvironment. In mice, the ligand for the…”
Get full text

Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy by van Elsas, Marit J, Middelburg, Jim, Labrie, Camilla, Roelands, Jessica, Schaap, Gaby, Sluijter, Marjolein, Tonea, Ruxandra, Ovcinnikovs, Vitalijs, Lloyd, Katy, Schuurman, Janine, Riesenfeld, Samantha J, Gajewski, Thomas F, de Miranda, Noel F C C, van Hall, Thorbald, van der Burg, Sjoerd H

“…Total tumor clearance through immunotherapy is associated with a fully coordinated innate and adaptive immune response, but knowledge on the exact contribution…”
Get more information

PLGA nanoparticles loaded with beta-lactoglobulin-derived peptides modulate mucosal immunity and may facilitate cow's milk allergy prevention by Kostadinova, Atanaska I., Middelburg, Jim, Ciulla, Michele, Garssen, Johan, Hennink, Wim E., Knippels, Leon M.J., van Nostrum, Cornelus F., Willemsen, Linette E.M.

“…Beta-lactoglobulin (BLG)-derived peptides may facilitate oral tolerance to whey and prevent cow's milk allergy (CMA). Loading of BLG-peptides in…”
Get full text

A Single-Domain TCR-like Antibody Selective for the Qa-1 b /Qdm Peptide Complex Enhances Tumoricidal Activity of NK Cells via Blocking the NKG2A Immune Checkpoint by Ghaffari, Soroush, Upchurch-Ange, Katherine, Gimlin, Susanne, Tripathi, Trivendra, Sluijter, Marjolein, Middelburg, Jim, van Hall, Thorbald, Weidanz, Jon

“…The NKG2A/HLA-E axis is an immune checkpoint that suppresses immune effector activity in the tumor microenvironment. In mice, the ligand for the NKG2A/CD94…”
Get full text